PE20221318A1 - Compuestos y composiciones para el tratamiento de enfermedades parasitarias - Google Patents
Compuestos y composiciones para el tratamiento de enfermedades parasitariasInfo
- Publication number
- PE20221318A1 PE20221318A1 PE2022000640A PE2022000640A PE20221318A1 PE 20221318 A1 PE20221318 A1 PE 20221318A1 PE 2022000640 A PE2022000640 A PE 2022000640A PE 2022000640 A PE2022000640 A PE 2022000640A PE 20221318 A1 PE20221318 A1 PE 20221318A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- compositions
- treatment
- 4alkyl
- parasitic diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/14—Adipic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Se refiere a compuestos de la Formula Ia donde; L es NCH3, O y S; Z es N o CR2; Y1 es C(R3)2; ONR3 y S; R1 es alquiloC1-4; hidroxialquilo C1-4, entre otros; R2 es H, alquilo C1-4, alcoxi C1-4, un anillo carbociclico, entre otros; R1 y R2 junto con los atomos a traves de los cuales estan conectados forman un anillo heterociclico de 3 a 6 miembros; R3 es H, alquiloC1-4, amino, entre otros; o una sal farmaceuticamente aceptable de los mismos, los cuales presentan actividad antiparasitaria como la malaria, entre otros.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962923915P | 2019-10-21 | 2019-10-21 | |
PCT/CN2020/122217 WO2021078120A1 (en) | 2019-10-21 | 2020-10-20 | Compounds and compositions for the treatment of parasitic diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20221318A1 true PE20221318A1 (es) | 2022-09-08 |
Family
ID=75492689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022000640A PE20221318A1 (es) | 2019-10-21 | 2020-10-20 | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
Country Status (17)
Country | Link |
---|---|
US (1) | US11597733B2 (es) |
EP (1) | EP4048678A4 (es) |
JP (1) | JP2022553261A (es) |
KR (1) | KR20220086619A (es) |
CN (1) | CN114787167A (es) |
AR (1) | AR120273A1 (es) |
BR (1) | BR112022007404A2 (es) |
CA (1) | CA3158333A1 (es) |
CO (1) | CO2022004768A2 (es) |
CR (1) | CR20220162A (es) |
EC (1) | ECSP22030740A (es) |
MX (1) | MX2022004665A (es) |
PE (1) | PE20221318A1 (es) |
TW (1) | TW202128709A (es) |
UY (1) | UY38928A (es) |
WO (1) | WO2021078120A1 (es) |
ZA (1) | ZA202204251B (es) |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO811630L (no) | 1980-05-29 | 1981-11-30 | Bayer Ag | Imidazoazolalkensyreamider, nye mellomprodukter for deres fremstilling, deres fremstilling og deres anvendelse som legemiddel |
DE3208437A1 (de) | 1982-03-09 | 1983-09-15 | Bayer Ag, 5090 Leverkusen | Imidazothiadiazolalkencarbonsaeureamide, neue zwischenprodukte zu ihrer herstellung, ihre herstellung und ihre verwendung in arzneimitteln |
US5017212A (en) | 1986-03-20 | 1991-05-21 | Takeda Chemical Industries, Ltd. | Sulfonylurea compounds and herbicidal use |
US8563550B2 (en) * | 2007-09-27 | 2013-10-22 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazolothiadiazoles for use as protein kinase inhibitors |
CA2732186A1 (en) * | 2008-07-29 | 2010-02-04 | Merck Patent Gmbh | Imidazothiadiazole derivatives |
EP2414369B1 (en) | 2009-04-02 | 2015-08-12 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Imidazo[2,1-b][1,3,4]thiadiazole derivatives |
WO2012020215A1 (en) * | 2010-08-09 | 2012-02-16 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors |
WO2012020217A1 (en) * | 2010-08-09 | 2012-02-16 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors |
WO2014015167A2 (en) | 2012-07-18 | 2014-01-23 | University Of Notre Dame Du Lac | 5,5-heteroaromatic anti-infective compounds |
JP2016500073A (ja) * | 2012-11-19 | 2016-01-07 | ノバルティス アーゲー | 寄生虫病の処置のための化合物および組成物 |
US10208030B2 (en) | 2016-04-08 | 2019-02-19 | Mankind Pharma Ltd. | GPR119 agonist compounds |
EP3490552B1 (en) | 2016-07-26 | 2022-11-23 | University of Southern California | Selective bromodomain inhibition of fungal bdf1 |
-
2020
- 2020-10-20 BR BR112022007404A patent/BR112022007404A2/pt unknown
- 2020-10-20 CN CN202080081635.2A patent/CN114787167A/zh active Pending
- 2020-10-20 PE PE2022000640A patent/PE20221318A1/es unknown
- 2020-10-20 CR CR20220162A patent/CR20220162A/es unknown
- 2020-10-20 EP EP20880049.0A patent/EP4048678A4/en active Pending
- 2020-10-20 CA CA3158333A patent/CA3158333A1/en active Pending
- 2020-10-20 MX MX2022004665A patent/MX2022004665A/es unknown
- 2020-10-20 WO PCT/CN2020/122217 patent/WO2021078120A1/en active Application Filing
- 2020-10-20 KR KR1020227016490A patent/KR20220086619A/ko unknown
- 2020-10-20 JP JP2022523080A patent/JP2022553261A/ja active Pending
- 2020-10-21 AR ARP200102912A patent/AR120273A1/es unknown
- 2020-10-21 US US17/076,126 patent/US11597733B2/en active Active
- 2020-10-21 UY UY0001038928A patent/UY38928A/es unknown
- 2020-10-21 TW TW109136510A patent/TW202128709A/zh unknown
-
2022
- 2022-04-13 CO CONC2022/0004768A patent/CO2022004768A2/es unknown
- 2022-04-14 ZA ZA2022/04251A patent/ZA202204251B/en unknown
- 2022-04-18 EC ECSENADI202230740A patent/ECSP22030740A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022553261A (ja) | 2022-12-22 |
CO2022004768A2 (es) | 2022-07-08 |
CA3158333A1 (en) | 2021-04-29 |
WO2021078120A1 (en) | 2021-04-29 |
EP4048678A4 (en) | 2023-10-18 |
MX2022004665A (es) | 2022-05-25 |
CN114787167A (zh) | 2022-07-22 |
KR20220086619A (ko) | 2022-06-23 |
US20210115065A1 (en) | 2021-04-22 |
ECSP22030740A (es) | 2022-05-31 |
CR20220162A (es) | 2022-08-08 |
TW202128709A (zh) | 2021-08-01 |
UY38928A (es) | 2021-05-31 |
BR112022007404A2 (pt) | 2022-07-05 |
ZA202204251B (en) | 2024-01-31 |
EP4048678A1 (en) | 2022-08-31 |
AR120273A1 (es) | 2022-02-09 |
US11597733B2 (en) | 2023-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2022000278A (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
PE20011371A1 (es) | Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5 | |
EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
AR054799A1 (es) | Derivados de oxindol | |
PE20160608A1 (es) | Compuestos de quinolina selectivamente sustituida | |
AR087046A2 (es) | Compuestos derivados de 4-oxoquinolina | |
AR057131A1 (es) | Derivados de purina como inmunomodulador | |
PE20091621A1 (es) | Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen | |
AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
AR079648A1 (es) | Inhibidores de la replicacion del virus de la hepatitis c | |
AR081075A1 (es) | Derivados de imidazo[1,2-c]pirimidina, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes e inflamatorias. | |
AR048939A1 (es) | Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios. | |
AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
CY1108908T1 (el) | Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4 | |
PE20181304A1 (es) | Derivados de indol n-sustituidos como moduladores de los receptores de pge2 | |
PE20161225A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
AR055431A1 (es) | Derivados del acido 4-amino-tieno[3,2-c]piridina-7-carboxilico | |
AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
CR20150419A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
AR065583A1 (es) | Compuestos macrociclicos y composicion farmaceutica | |
AR076401A1 (es) | Bisaril alquinilamidas como moduladores alostericos negativos del receptor metabotropico de glutamato 5 (mglur5) | |
MA39707B1 (fr) | Dérivés de 1,2-dihydro-3h-pyrrolo [1,2-c]imidazol-3-one et leur utilisation comme agents antibactériens | |
AR087470A1 (es) | Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen |